[PAGID] Wiskott-Aldrich study

[Jordan Orange]

Dear Colleagues,

We have recently received IRB approval and an IND from the FDA to  
begin a Phase-I safety and tolerability study of IL-2 in The Wiskott- 
Aldrich syndrome.

We are currently looking for collaborators and patients for our study.

Our study is motived by the observation that in Wiskott-Aldrich  
syndrome NK cell function and actin dynamics can be restored ex vivo  
by exposure to IL-2.

The study consists of three 5 day courses of low-dose IL-2  
administered subcutaneously over 9 months.  It is intended for  
patients who do not have plans for hematopoietic stem cell  
transplantation.  The study will involve 3-5 visits to the Children's  
Hospital of Philadelphia.  One will include an inpatient stay in our  
Clinical and Translational Research center for the duration of the  
initial IL-2 treatment cycle.  Others will include shorter stays.   
Patient travel will be supported by the study.

Details of the study with inclusion and exclusion criteria as well as  
protocol information (blood draws, visit timeline, etc.) can be found  
on ClinicalTrials.gov at:
http://clinicaltrials.gov/ct2/show/NCT00774358

Additional detail and protocol information is available at www.wastherapy.com

Please contact us if you have any interest or questions.

Thank you for reading this email,

Jordan

Jordan Orange MD/PhD
University of Pennsylvania School of Medicine
Children's Hospital of Philadelphia, Division of Immunology
3615 Civic Center Blvd,  ARC-1016H
Philadelphia, PA 19104
(Voice) 267-426-5622

Sumita Roy-Ghanta, MD
Instructor, Allergy and Immunology
34th and Civic Center Boulevard
Orange Laboratory, Abramson Research Building 1016
Philadelphia, PA 19104
(Voice): 267-426-7772
Email: ROYGHANTAS at email.chop.edu
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://seven.pairlist.net/mailman/private/pagid/attachments/20081126/3fa4ae4f/attachment.htm>